Literature DB >> 33045738

Diffusion MRI as an early marker of response to immune checkpoint inhibitors.

Janine M Lupo1.   

Abstract

Keywords:  ADC; diffusion MRI; glioma; immune checkpoint inhibitors; immunotherapy; response to therapy

Mesh：

Substances：

Year:  2020        PMID： 33045738      PMCID： PMC7690350          DOI： 10.1093/neuonc/noaa224

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

Review 1.  Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.

Authors:  Harpreet Hyare; Steffi Thust; Jeremy Rees
Journal:  Curr Treat Options Neurol       Date:  2017-03       Impact factor: 3.598

Review 2.  Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.

Authors:  Sarah J Nelson
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

3.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Authors:  F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jeffrey S Weber; Adil Daud; Omid Hamid; Amita Patnaik; Antoni Ribas; Caroline Robert; Tara C Gangadhar; Anthony M Joshua; Peter Hersey; Roxana Dronca; Richard Joseph; Darcy Hille; Dahai Xue; Xiaoyun Nicole Li; S Peter Kang; Scot Ebbinghaus; Andrea Perrone; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-03-07       Impact factor: 44.544

4.  Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.

Authors:  Joseph Song; Priyanka Kadaba; Amanda Kravitz; Adilia Hormigo; Joshua Friedman; Puneet Belani; Constantinos Hadjipanayis; Benjamin M Ellingson; Kambiz Nael
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

5.  Retrospective study of nivolumab for patients with recurrent high grade gliomas.

Authors:  Megan Mantica; Ashley Pritchard; Frank Lieberman; Jan Drappatz
Journal:  J Neurooncol       Date:  2018-05-19       Impact factor: 4.130

Review 6.  Immunotherapy advances for glioblastoma.

Authors:  David A Reardon; Gordon Freeman; Catherine Wu; E Antonio Chiocca; Kai W Wucherpfennig; Patrick Y Wen; Edward F Fritsch; William T Curry; John H Sampson; Glenn Dranoff
Journal:  Neuro Oncol       Date:  2014-09-04       Impact factor: 12.300

Review 7.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Authors:  Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon
Journal:  Lancet Oncol       Date:  2015-11       Impact factor: 41.316
  7 in total
  2 in total

Review 1.  High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.

Authors:  Otto M Henriksen; María Del Mar Álvarez-Torres; Patricia Figueiredo; Gilbert Hangel; Vera C Keil; Ruben E Nechifor; Frank Riemer; Kathleen M Schmainda; Esther A H Warnert; Evita C Wiegers; Thomas C Booth
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 5.738

2.  White matter alterations in pediatric brainstem glioma: An national brain tumor registry of China study.

Authors:  Peng Zhang; Guocan Gu; Yunyun Duan; Zhizheng Zhuo; Changcun Pan; Pengcheng Zuo; Yi Wang; Xiaoou Li; Zhuang Jiang; Liying Qu; Yaou Liu; Liwei Zhang
Journal:  Front Neurosci       Date:  2022-09-09       Impact factor: 5.152
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.